Status:
NOT_YET_RECRUITING
Predictors of GON Blockade Success in Migraine
Lead Sponsor:
Başakşehir Çam & Sakura City Hospital
Collaborating Sponsors:
Umraniye Education and Research Hospital
Gaziantep City Hospital
Conditions:
Migraine
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This multicenter, prospective cohort study aims to identify clinical and demographic predictors that influence the success of greater occipital nerve (GON) block in patients with migraine. Patients w...
Eligibility Criteria
Inclusion
- Diagnosis of migraine for at least 6 months, according to ICHD-3 criteria
- Age between 18 and 65 years
- Inadequate response to preventive therapy used regularly for at least 3 months
- Planned treatment with greater occipital nerve block (GONB) and provision of signed informed consent
- Receiving GONB treatment for the first time
Exclusion
- Pregnancy or breastfeeding
- Presence of malignancy
- Coagulopathy or anticoagulant therapy
- Local infection, open wound, or history of surgery at the injection site preventing the procedure
- History of severe neurological or psychiatric disorders
- Receipt of interventional treatment (e.g., Botox, acupuncture, neural therapy, nerve blocks) within the last 3 months
- Use of steroids or immunosuppressive therapy
- Start of a new preventive therapy within the last 3 months
- Inability to comply with keeping a headache diary
- Known hypersensitivity or allergy to bupivacaine
Key Trial Info
Start Date :
September 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT07170111
Start Date
September 15 2025
End Date
December 1 2026
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Başakşehir Çam and Sakura City Hospital
Istanbul, Turkey (Türkiye)